Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340381 | 0.82 | LMNA (0.38) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24832683 | 0.80 | ERN1 (0.44) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28178629 | 0.79 | ALDH1A1 (0.53) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23240183 | 0.79 | TRPA1 (0.60) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5203307 | 0.79 | ALDH1A1 (0.53) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30138202 | 0.78 | NFE2L2 (0.56) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13615662 | 0.78 | NFE2L2 (0.56) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL149582 | 0.77 | CYP1A2 (0.58) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3402801 | 0.77 | CYP1A2 (0.58) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL26552230 | 0.77 | TRPA1 (0.46) | NFE2L2TRPA1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002663-A1 | SELECTIVE SALMONELLA OR E. COLI CULTIVATION METHOD, COMPOSITIONS AND USES | Solus Scientific Solutions Ltd (GB) | 2022-01-06 | — | — | US | disclosed |
| EP-3115357-B1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | RES & INNOVATION UK (GB) | 2020-08-12 | — | — | EP | disclosed |
| EP-1736471-B1 | 3-(DIHYDRO(TETRAHYDRO)ISOQUINOLIN-1-YL)QUINOLINES | MITSUI CHEMICALS AGRO INC (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-7632783-B2 | fungicides, pesticides for protecting rice crop, tomatoes, cucumbers and green beans; 3-(5-fluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline | MITSUI CHEMICALS AGRO, INC. (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20080275242-A1 | 3-(Dihydro(Tetrahydro)Isoquinolin-1-Yl)Quinoline Compound | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080096894-A1 | Anti-Bacterial Compounds | ASTON UNIVERSITY (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096894-A1 | Anti-Bacterial Compounds | ASTON UNIVERSITY (GB) | 2008-04-24 | — | — | US | disclosed |
| CN-1324015-C | Pyridine and pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| CN-1989101-A | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands | WYETH CORP (US) | 2007-06-27 | — | — | CN | disclosed |
| EP-1736471-A1 | 3-(DIHYDRO(TETRAHYDRO)ISOQUINOLIN-1-YL)QUINOLINES | Sankyo Agro Company, Limited (JP) | 2006-12-27 | — | — | EP | disclosed |
| CN-1630644-A | Novel pyridine and pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | CN | disclosed |
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | disclosed |
| EP-0667864-B1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | ZENECA LTD (GB) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275242-A1 | 3-(Dihydro(Tetrahydro)Isoquinolin-1-Yl)Quinoline Compound | QTRT1, RABL3, RECQL | NFE2L2 1109/4885TRPA1 2092/4885CYP1A2 171/4885 |
| US-20080096894-A1 | Anti-Bacterial Compounds | MRPL21, PGLS, FOSB | NFE2L2 2689/4885TRPA1 2552/4885CYP1A2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.